Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone412-586-5830
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees37
Next Earnings Date11/4/2019 (Estimated)
OptionableNot Optionable
Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions
What is Krystal Biotech's stock symbol?
Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."
How were Krystal Biotech's earnings last quarter?
Krystal Biotech Inc (NASDAQ:KRYS) posted its quarterly earnings results on Monday, August, 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by $0.05. View Krystal Biotech's Earnings History.
When is Krystal Biotech's next earnings date?
What price target have analysts set for KRYS?
7 Wall Street analysts have issued 1-year target prices for Krystal Biotech's shares. Their forecasts range from $34.00 to $81.00. On average, they expect Krystal Biotech's share price to reach $61.80 in the next twelve months. This suggests a possible upside of 71.3% from the stock's current price. View Analyst Price Targets for Krystal Biotech.
What is the consensus analysts' recommendation for Krystal Biotech?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Krystal Biotech.
What are Wall Street analysts saying about Krystal Biotech stock?
Here are some recent quotes from research analysts about Krystal Biotech stock:
- 1. According to Zacks Investment Research, "Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. " (10/9/2019)
- 2. Cowen Inc analysts commented, "On 8/9, Intec reported 2Q19 with a net loss of ($10M) and ended the period with $21.6M in cash on the balance sheet. Operating expenses are expected to be reduced with the P3 trial in Parkinson’s disease now over. The company is evaluating the data for AP-CD/LD to determine what the next steps may be. While the P3 trial outcome was a disappointment, it’s worth noting that the delivery technology that is the foundation of Intec as a company, did deliver the levodopa as it was supposed to. In addition, there are subgroup data that suggest trial design could be different and potentially have success, in our view. Nonetheless, it’s too early to tell and as we await more clarity, we remain Hold rated." (8/15/2019)
- 3. Chardan Capital analysts commented, "We view the receipt of the FDA Therapy (RMAT) designation as a significant positive for the timelines on KB103. This news follows KB103 receiving the EMA Priority Medicines (PRIME) designation on 29 March. As we have noted, Krystal’s market cap is modest relative to companies with PRIME and/or RMAT/BTD designations. We again reiterate: We would not be surprised if Krystal’s market cap crosses $1 billion by 2020E. On today’s news, we update our detailed model, moving the probability of KB103 launch from 55% to 67%, leading to an increase in our 2030E KB103 sales estimate from $492.1 mm to $596.5 mm. With a reduction in our WACC from 12.4% to 11.9%, these changes lead to a 30% KRYS PT target increase, from $57.50 to $75. has demonstrated impressive wound closure data (albeit in small numbers of patients) in the GEM-1 and GEM-2 studies." (6/24/2019)
- 4. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are increasing our target to $38 from $32. The changes to our valuation include: (1) adjustment to base year to reflect the current NPV relative to our September 2018 initiation of coverage; and (2) increasing our projected chance of success for to 15%. We are currently leaving our projected chance of success for KB103 the same, at 25%, and await the pending clinical update this quarter." (5/24/2019)
- 5. William Blair analysts commented, "We continue to view the anticipated second quarter clinical update of the GEM trial as a significant near-term catalyst for shares. As we have noted previously (see our note, We See Durable Wound Closure and 30%-40% COL7A1 Expression as after reviewing the published literature, we believe that achieving roughly 30%-40% of wild-type (normal) levels of collagen VII could be sufficient to restore skin integrity and prevent skin blistering. We also believe that the presence of anchoring fibrils should be viewed qualitatively only due to its lack of direct correlation with clinical results." (5/6/2019)
Has Krystal Biotech been receiving favorable news coverage?
Media coverage about KRYS stock has trended neutral this week, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Krystal Biotech earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Krystal Biotech.
Are investors shorting Krystal Biotech?
Krystal Biotech saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,440,000 shares, an increase of 25.2% from the August 30th total of 1,150,000 shares. Based on an average daily volume of 171,000 shares, the days-to-cover ratio is presently 8.4 days. Currently, 13.4% of the shares of the stock are sold short. View Krystal Biotech's Current Options Chain.
Who are some of Krystal Biotech's key competitors?
Some companies that are related to Krystal Biotech include Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Regenxbio (RGNX), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE) and Aerie Pharmaceuticals (AERI).
What other stocks do shareholders of Krystal Biotech own?
Who are Krystal Biotech's key executives?
Krystal Biotech's management team includes the folowing people:
- Mr. Krish S. Krishnan, Pres, CEO & Chairman (Age 54)
- Ms. Suma M. Krishnan, Founder, COO & Director (Age 54)
- Ms. Pooja Agarwal, VP of Product Devel. (Age 40)
- Mr. Antony A. Riley, Chief Financial Officer (Age 51)
- Ms. Gloria Lin, Accounting Mang.
When did Krystal Biotech IPO?
(KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.
Who are Krystal Biotech's major shareholders?
Krystal Biotech's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Garnet Equity Capital Holdings Inc. (0.16%) and Comprehensive Portfolio Management LLC (0.05%). Company insiders that own Krystal Biotech stock include Antony A Riley, Daniel Janney, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Institutional Ownership Trends for Krystal Biotech.
Which major investors are selling Krystal Biotech stock?
How do I buy shares of Krystal Biotech?
Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Krystal Biotech's stock price today?
One share of KRYS stock can currently be purchased for approximately $36.07.
How big of a company is Krystal Biotech?
Krystal Biotech has a market capitalization of $624.01 million. The company earns $-10,890,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Krystal Biotech employs 37 workers across the globe.View Additional Information About Krystal Biotech.
What is Krystal Biotech's official website?
How can I contact Krystal Biotech?
Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830.
MarketBeat Community Rating for Krystal Biotech (NASDAQ KRYS)
MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote "Outperform" if you believe KRYS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days.
